There's a new month around the corner, which means we have some companies for you to consider. --------------------------------------------------------------------------------------------------
5 Top Stocks for September
| | | It's back to school season and if one of the items on your to-do list is finding options for your investment portfolio, we have a few suggestions of companies you might want to evaluate. - Stitch Fix (NASDAQ:SFIX): The styling service and apparel company that's disrupting the U.S. clothing market is on sale. Since its recent peak on July 1, the stock has fallen about 40% as investors worry about trade war implications and Amazon's interest in the space. But those headwinds aren't new and there's a long-term case for Stitch Fix. It's equipped to benefit from consumer-driven trends toward e-commerce and personalization. It's also been profitable for several years, with management targeting at least 20% revenue growth long term.
- Autodesk (NASDAQ:ADSK): The software-as-a-service company sells leading products for a range of industries including architecture, engineering, manufacturing, education, and entertainment. Its existing customers are spending more on Autodesk products each year — meaning they make more money without adding another customer. And management is working on convincing 13 million legacy users on old licensing deals to upgrade to the new, more business-friendly subscription model. Those two forces should help propel growth rates steadily upward.
- Simon Property Group (NYSE:SPG): The REIT (real estate investment trust) is one of the largest in the U.S. and shouldn't be overlooked just because it operates in the retail industry. Many of Simon's malls are valuable, upscale shopping destinations and the company has vast advantages with a dominant market share. The company actively works to incorporate trends, such as esports and co-working spaces, to keep its properties current. And it's so successful bringing shoppers in the door, Simon's retail tenants have reported average sales per square foot growth — not a decline.
Read the rest. | |
Already subscribed to a premium service? Click here to view your subscriptions. Not a member yet? Click here to sign up!
| | Watch: How Tesla Made Electric Cars Cool
| | | We're taking a closer look at the fits and starts electric vehicles have experienced in recent decades, why some automakers are choosing to make hybrids vs. electric cars, and what the future might hold. | |
How to Invest in Utility Stocks Utility stocks are generally seen as safe havens for investors because their products and services are considered necessities. Although utility stocks typically do not offer huge growth potential, a slow and steady income producer can be a desirable investment option for those seeking calmer waters in a turbulent stock market. But utility stocks are available in a broad spectrum of investment options and require more than just a surface look to identify the best opportunities for an investment portfolio. This long read offers a detailed primer on how to familiarize yourself with this sector, ranging from the critical differences between regulated and unregulated utility companies, how to gauge the value of a utility company and its assets, what key metrics to keep in mind, and more. Read the rest here.
| | | An Oklahoma judge this week ordered Johnson & Johnson to pay $572 million for the company's role in the state's opioid crisis. The state had sought more than $17 billion in damages. Analysts Andy Cross and Jason Moser discuss the future of the company and more. | | | | Not sure what to ask your smart speaker? Keep up with what's happening in the market by adding our daily flash briefing to your home assistant. Just look for The Motley Fool on your Amazon Alexa or Google Home app, click subscribe, and then you're good to go. | |
Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win Amgen (NASDAQ:AMGN) CEO Bob Bradway said in the big biotech's second-quarter conference call last month that Amgen was "looking at ways to grow through business development." We now know one of those ways. Earlier this week, Amgen announced that it was buying psoriasis and psoriatic arthritis drug Otezla from Celgene (NASDAQ:CELG) for $13.4 billion in cash. This appears to be a relatively rare deal where every company involved wins, let's take a look at how. - Without selling Otezla, Bristol-Myers Squibb (NYSE:BMY)'s pending acquisition of Celgene would be a no-go due to Federal Trade Commission concerns. That deal is especially important to BMS, and this sale should clear the way. The cash doesn't hurt, either.
- Otezla might be a perfect fit for Amgen, which already has an established immunology sales teams that promotes Enbrel and Humira biosimilar Amgevita. The company also expects to reap tax benefits from the deal, and Otezla's sales are likely to keep growing by low double-digit percentages over the next five years.
Read the rest. | |
Easily track your favorite stocks with our new browser extension for Google Chrome. Add it to Chrome by going here, then open a new tab and use the "Manage Tickers" button to customize the page with your favorite stocks.
| | Quick Reads - Netflix's market share is shrinking, but it's still the king of video streaming.
- Disney needs to fix its fading theme park, as Epcot is struggling to keep up with its peers.
- Philip Morris International and Altria have opened discussions of a possible merger. Here are 4 reasons why PMI shouldn't want to.
| |
Social Media Post of the Week
| | | | |
没有评论:
发表评论